[Initial results of clinical research on a tabletted form of ethacizin (the diethylamino analog of ethmozine) in ventricular arrhythmias].
The clinical effectiveness, pharmacodynamics and some pharmacokinetic aspects of a new antiarrhythmic drug ethacyzin (a diethylamine analogue of ethmozin) were studied, using diurnal electrocardiographic monitoring and exercise testing, in 50 patients with frequent and chronic ventricular heart rhythm disorders. The drug had positive antiarrhythmic effect in 87-90% of patients treated with single 100-150 mg oral doses and courses of 150-300 mg daily (the mean dose being 200 +/- 50 mg). With a single oral dose of 100 mg ethacyzin, the onset, peak and overall duration of its therapeutic effect were noted at 0.5-1, 1.5-2 and 6-8 hours, respectively. The minimal therapeutic plasma ethacyzine concentration was 40-70 ng/ml. Both in acute testing and during treatment courses, the drug significantly expanded the P wave, the P-Q interval and the QRS complex of the electrocardiogram, without affecting heart rate or Q-T duration, the magnitude of the resulting change in the said parameters depending on the dose administered and the antiarrhythmic effect of ethacyzin.